News
YOLT-203 is the first in vivo gene-editing therapy to show positive clinical data for PH1. In August 2024, YOLT-203 was the first investigational in vivo gene-editing therapy to enter clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback